3,9-Diazabicyclo[3.3.1]non-6-ene-6-carboxaMide, N-cyclopropyl-7-[4-[2-(2,6-dichloro-4-Methylphenoxy)ethoxy]phenyl]-N-[(2,3-diMethylphenyl)Methyl]-, (1R,5S)- manufacturers
- MK-8141
-
- $3380.00
-
2026-05-21
- CAS:903579-36-2
- Purity:
- Supply Ability: 10g
|
| | 3,9-Diazabicyclo[3.3.1]non-6-ene-6-carboxaMide, N-cyclopropyl-7-[4-[2-(2,6-dichloro-4-Methylphenoxy)ethoxy]phenyl]-N-[(2,3-diMethylphenyl)Methyl]-, (1R,5S)- Basic information |
| Product Name: | 3,9-Diazabicyclo[3.3.1]non-6-ene-6-carboxaMide, N-cyclopropyl-7-[4-[2-(2,6-dichloro-4-Methylphenoxy)ethoxy]phenyl]-N-[(2,3-diMethylphenyl)Methyl]-, (1R,5S)- | | Synonyms: | 3,9-Diazabicyclo[3.3.1]non-6-ene-6-carboxaMide, N-cyclopropyl-7-[4-[2-(2,6-dichloro-4-Methylphenoxy)ethoxy]phenyl]-N-[(2,3-diMethylphenyl)Methyl]-, (1R,5S)-;(1R,5S)-N-cyclopropyl-7-(4-(2-(2,6-dichloro-4-methylphenoxy)ethoxy)phenyl)-N-(2,3-dimethylbenzyl)-3,9-diazabicyclo[3.3.1]non-6-ene-6-carboxamide;(1R,5S)-N-cyclopropyl-7-[4-[2-(2,6-dichloro-4-methylphenoxy)ethoxy]phenyl]-N-[(2,3-dimethylphenyl)methyl]-3,9-diazabicyclo[3.3.1]non-6-ene-6-carboxamide | | CAS: | 903579-36-2 | | MF: | C35H39Cl2N3O3 | | MW: | 620.60846 | | EINECS: | | | Product Categories: | | | Mol File: | 903579-36-2.mol | ![3,9-Diazabicyclo[3.3.1]non-6-ene-6-carboxaMide, N-cyclopropyl-7-[4-[2-(2,6-dichloro-4-Methylphenoxy)ethoxy]phenyl]-N-[(2,3-diMethylphenyl)Methyl]-, (1R,5S)- Structure](CAS/GIF/903579-36-2.gif) |
| | 3,9-Diazabicyclo[3.3.1]non-6-ene-6-carboxaMide, N-cyclopropyl-7-[4-[2-(2,6-dichloro-4-Methylphenoxy)ethoxy]phenyl]-N-[(2,3-diMethylphenyl)Methyl]-, (1R,5S)- Chemical Properties |
| Boiling point | 803.2±65.0 °C(Predicted) | | density | 1.31±0.1 g/cm3(Predicted) | | pka | 8.71±0.60(Predicted) |
| | 3,9-Diazabicyclo[3.3.1]non-6-ene-6-carboxaMide, N-cyclopropyl-7-[4-[2-(2,6-dichloro-4-Methylphenoxy)ethoxy]phenyl]-N-[(2,3-diMethylphenyl)Methyl]-, (1R,5S)- Usage And Synthesis |
| Uses | MK-8141 (ACT-077825) is a renin inhibitor that significantly increases levels of immunoreactive renin (ir-AR) by sevenfold but does not result in sustained reductions in blood renin activity (PRA). This study evaluated the antihypertensive efficacy of MK-8141 in hypertensive disease. Despite its effects on ir-AR, MK-8141 (ACT-077825) did not produce significant blood pressure-lowering effects in the absence of sustained PRA inhibition. | | References | [1] Design and Preparation of Potent, Nonpeptidic, Bioavailable Renin Inhibitors
J. Med. Chem., 2009, 52 (12), pp 3689-3702 DOI:10.1016/j.jash.2010.06.006 |
| | 3,9-Diazabicyclo[3.3.1]non-6-ene-6-carboxaMide, N-cyclopropyl-7-[4-[2-(2,6-dichloro-4-Methylphenoxy)ethoxy]phenyl]-N-[(2,3-diMethylphenyl)Methyl]-, (1R,5S)- Preparation Products And Raw materials |
|